L
L. Zhang
Researcher at Eli Lilly and Company
Publications - 18
Citations - 1248
L. Zhang is an academic researcher from Eli Lilly and Company. The author has contributed to research in topics: Ixekizumab & Psoriasis Area and Severity Index. The author has an hindex of 12, co-authored 18 publications receiving 1020 citations.
Papers
More filters
Journal ArticleDOI
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials
Christopher E.M. Griffiths,Kristian Reich,Mark Lebwohl,Peter C.M. van de Kerkhof,Carle Paul,Alan Menter,Gregory S Cameron,J. Erickson,L. Zhang,Roberta J. Secrest,Susan Ball,Daniel K. Braun,Olawale Osuntokun,Michael P. Heffernan,Brian J. Nickoloff,Kim A. Papp +15 more
TL;DR: Two studies of ixekizumab compared with placebo or etanercept to assess the safety and efficacy of specifically targeting interleukin 17A in patients with widespread moderate-to-severe psoriasis met the primary endpoints.
Journal ArticleDOI
Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3).
Andrew Blauvelt,Melinda Gooderham,Lars Iversen,Susan Ball,L. Zhang,Noah Agada,Kristian Reich +6 more
TL;DR: Ixekizumab is well tolerated and demonstrates persistent efficacy through 108 weeks of treatment in UNCOVER‐3, and the 108‐week as‐observed, multiple imputation (MI), and modified MI (mMI) methods summarized.
Journal ArticleDOI
Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3).
Kim A. Papp,Craig L. Leonardi,Andrew Blauvelt,Kristian Reich,Neil J. Korman,Mamitaro Ohtsuki,Carle Paul,Susan Ball,Gregory S Cameron,J. Erickson,L. Zhang,Lotus Mallbris,Christopher E.M. Griffiths +12 more
TL;DR: Ixekizumab, a high‐affinity monoclonal antibody that selectively targets interleukin (IL)‐17A, is approved for the treatment of moderate‐to‐severe psoriasis.
Journal ArticleDOI
Ixekizumab treatment improves fingernail psoriasis in patients with moderate-to-severe psoriasis: results from the randomized, controlled and open-label phases of UNCOVER-3
P.C.M. van de Kerkhof,Lyn Guenther,Alice B. Gottlieb,M. Sebastian,Jashin J. Wu,Peter Foley,Akimichi Morita,Orin Goldblum,L. Zhang,J. Erickson,Susan Ball,Phoebe Rich +11 more
TL;DR: Fingernail psoriasis is difficult to treat and can cause itching and rashes that can be painful and painful to treat.
Journal ArticleDOI
Pomaglumetad Methionil (LY2140023 Monohydrate) and Aripiprazole in Patients with Schizophrenia: A Phase 3, Multicenter, Double-Blind Comparison
TL;DR: Long-term treatment with pomaglumetad methionil resulted in significantly less weight gain than aripiprazole, and no statistically significant differences in the incidence of TEAEs, EPS, or suicidal ideation or behavior were noted between treatment groups.